alex3619
Senior Member
- Messages
- 13,810
- Location
- Logan, Queensland, Australia
I posted a comment on his blog:
As a patient I was very pleased to read your analysis. Its obviously of interest to a great many patients. I wonder though how many in science, the medical profession, and related government and industry organizations will be interested. They should be, very much so, but there is a long history of problems with this kind of research being ignored.
I do hope you write a follow-up article.
It is still a mystery to me why a disease that costs the world on the order of a 100 billion dollars per year (projected from estimates in the USA) does not receive more scrutiny, and the science taken more seriously. Anyone with financial interest in outcomes, not just patients, should in theory want to see the most robust science, and should not tolerate science that fails to meet reasonable criteria.
I have long regarded the PACE trial as far below evidence based Gold Standard, due to not being double blinded, the use of a manufactured and irrelevant comparison arm with adaptive pacing, and the heavy reliance of subjective measures in a psychological intervention trial. There is provision within Evidence Based Medicine to downgrade the ranking of trial results due to problems. These alone prevent it being Gold Standard (though this is a nebulous and debatable term), before you even get to effect sizes, statistical and methodological errors, and so on.
I wonder what you think about the PACE trial's papers from an evidence based perspective?